multiple myeloma

Basketball players hands reaching for a ball near the hoop during a professional game
Biotech

Exicure scores in phase 2 multiple myeloma program

Since market open, Exicure’s stock has shot up 65%, rising from Friday’s close of $5.27 per share to $8.73 as of 10:10 a.m. ET today.
Gabrielle Masson Dec 9, 2025 10:15am
JNJ
Favicon Fierce Pharma

ASH: J&J pressures CAR-T with Tecvayli combo in 2L myeloma

Dec 9, 2025 7:30am
Gilead and Kites exhibit booth at ASH 2025

ASH: Anito-cel strengthens potential as Kite preps for launch

Dec 7, 2025 11:52am
Legend
Favicon Fierce Pharma

J&J, Legend pull ASH paper comparing Carvykti to rival CAR-T

Nov 12, 2025 11:36am
pipeline pipes RD research

Cullinan puts kibosh on 2 cancer assets amid autoimmune refocus

Nov 6, 2025 1:26pm
HailshadowGettyImages

DNA and RNA testing helps identify blood cancer relapse risks

Oct 13, 2025 10:00am